Revelation Biosciences announced that the Phase 1b CLEAR challenge study of its REVTx-99b intranasal phosphorylated hexaacylated disaccharide (PHAD) in participants with allergies to rye grass pollen showed that the nasal drops were safe and well tolerated but failed to demonstrate any reduction of allergy symptoms or improvement in breathing. The company said that, “Revelation management plans to evaluate future development of this and other ongoing programs.”
In October 2021, Revelation announced plans for the Phase 1b study of REVTx-99b after raising $4.4 million to develop REVTx-99 for indications beyond viral respiratory infections. Earlier this year, Revelation announced that a Phase 2b challenge study of REVTx-99a for the prevention of H3N2 influenza also failed meet its primary endpoint, producing no significant reduction in viral load in the nose compared to placebo.
Read the Revelation Biosciences press release.
